# US 2020/0348319 A1 · Diagnosis and treatment of autism spectrum disorders based on amine containing metabotypes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0348319 A1
- Document ID: US20200348319A1
- Status: Published application
- Kind: A1
- Application number: 16/961,995
- Filed: 2019-01-29
- Published: 2020-11-05
- Earliest claimed: 2018-01-29
- Assignees: Stemina Biomarker Discovery, Inc.
- Applicants: Stemina Biomarker Discovery, Inc.
- Inventors: Alan M. Smith; Joseph King; Paul R. West; Michael Ludwig; Elizabeth L.R. Donley; Robert Burrier
- Web page: https://patentgrep.com/patent/US20200348319A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 2800/30: Psychoses; Psychiatry
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides methods of diagnosing autism spectrum disorders (ASD) by analyzing ratios of concentrations of selected amine containing compounds in a sample, such as a blood sample, from a subject. Based on the discovery that specific amine containing compounds and their ratios are dysregulated in patients with ASD, these metabotypes or subtypes of metabolism have the potential to diagnose earlier and suggest more precise treatment based on the metabolism of the individual. The invention provides methods of analyzing amine containing compounds and ratios in a test subject and determining whether the test subject has or is at risk of developing an ASD by comparing ratios from the test subject to ratios from subjects diagnosed with a neurodevelopmental disorder such as ASD who share a common profile of metabolism which is not found in the majority of typically developing subjects. The invention also provides methods of determining a course of treatment for an individual that has or is at risk of developing an ASD based on the individuals metabotype.

## Claims

### Claim 1

A method of providing guidance for treating a subject that has or is at risk of developing a neurodevelopmental disorder, the method comprising:
receiving results of an assay in which concentrations of at least two amine containing compounds are measured in a sample from a subject that has or is at risk of developing a neurodevelopmental disorder, the results comprising at least one ratio of concentrations of the at least two amine containing compounds; and
if the at least one ratio indicates an imbalance of the at least two amine containing compounds based on comparison to a reference ratio, providing guidance for treating the subject that has or is suspected of having a neurodevelopmental disorder.

### Claim 2 (depends on 1)

The method of claim 1, wherein the neurodevelopmental disorder is an autism spectrum disorder.

### Claim 3 (depends on 1)

The method of claim 1, wherein the at least one ratio of concentrations is selected from the group consisting of ethanolamine to (Glu and kynurenine); Gln to Ile; Gln to Leu; Gln to Val; Gly to Asn; Gly to Glu; Gly to Ile; Gly to Leu; Gly to Lys; Gly to Phe; Gly to Val; hypoxanthine to uric acid; Orn to Ile; Orn to kynurenine; Orn to Leu; Orn to Lys; Orn to Phe; Orn to Val; Ser to Ile; Ser to Leu; Ser to Val; and xanthine to uric acid.

### Claim 4 (depends on 3)

The method of claim 3, wherein the at least one ratio of concentrations comprises a plurality of ratios selected from the group consisting of:
(A) Gln to Ile; Gln to Leu; and Gln to Val,
(B) Gly to Ile; Gly to Leu; and Gly to Val,
(C) Orn to Ile; Orn to Leu; and Orn to Val,
(D) Ser to Ile; Ser to Leu; and Ser to Val, and
(E) hypoxanthine to uric acid; and xanthine to uric acid.

### Claim 5 (depends on 1)

The method of claim 1, wherein the at least one ratio is selected from the group consisting of Orn to Ile; Orn to Leu; and Orn to Val, and wherein if the at least one ratio indicates an imbalance, the guidance indicates that the subject has metabolic dysregulation.

### Claim 6 (depends on 1)

The method of claim 1, wherein the at least one ratio comprises a plurality of ratios comprising Orn to Ile; Orn to Leu; and Orn to Val, and wherein if each of the plurality of ratios indicates an imbalance, the guidance indicates that the subject has or is at risk of developing the neurodevelopmental disorder.

### Claim 7 (depends on 1)

The method of claim 1, wherein:
the reference ratio is from a subset of autism spectrum disorder (ASD) subjects; and
the at least one ratio matches the reference ratio.

### Claim 8 (depends on 7)

The method of claim 7, wherein the at least one ratio is different from a ratio of concentrations of the at least two amine containing compounds in subjects that are developmentally delayed.

### Claim 9 (depends on 1)

The method of claim 1, wherein the reference ratio is from typically developing subjects; and
the at least one ratio does not match the reference ratio.

### Claim at position 10

10-15. (canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein the sample comprises a body fluid selected from the group consisting of blood, plasma, urine, sweat, tears, serum, stool, and saliva.

### Claim 17

A method of determining whether a test subject has or is at risk of developing a neurodevelopmental disorder, the method comprising:
receiving a sample from a test subject that is suspected of having or being at risk of developing a neurodevelopmental disorder;
conducting a mass spectrometry analysis on the sample to generate mass spectral data;
performing, via a computer, one or more algorithmic analyses on the mass spectral data to determine concentrations of at least two amine containing compounds in the sample;
generating, via the computer, at least one test ratio of concentrations of the at least two amino containing compounds; and
outputting the at least one test ratio to a report, wherein the report further comprises a reference ratio of concentrations of the at least two amino containing compounds and the report indicates if the at least one test ratio is imbalanced based on comparison to the reference ratio.

### Claim 18 (depends on 17)

The method of claim 17, wherein the neurodevelopmental disorder is an autism spectrum disorder.

### Claim 19 (depends on 17)

The method of claim 17, wherein the at least one ratio of concentrations is selected from the group consisting of ethanolamine to (Glu and kynurenine); Gln to Ile; Gln to Leu; Gln to Val; Gly to Asn; Gly to Glu; Gly to Ile; Gly to Leu; Gly to Lys; Gly to Phe; Gly to Val; hypoxanthine to uric acid; Orn to Ile; Orn to kynurenine; Orn to Leu; Orn to Lys; Orn to Phe; Orn to Val; Ser to Ile; Ser to Leu; Ser to Val; and xanthine to uric acid.

### Claim 20 (depends on 19)

The method of claim 19, wherein the at least one ratio of concentrations comprises a plurality of ratios selected from the group consisting of:
(A) Gln to Ile; Gln to Leu; and Gln to Val,
(B) Gly to Ile; Gly to Leu; and Gly to Val,
(C) Orn to Ile; Orn to Leu; and Orn to Val,
(D) Ser to Ile; Ser to Leu; and Ser to Val, and
(E) hypoxanthine to uric acid; and xanthine to uric acid.

### Claim 21 (depends on 17)

The method of claim 17, wherein the at least one ratio is selected from the group consisting of Orn to Ile; Orn to Leu; and Orn to Val, and wherein if the at least one ratio indicates an imbalance, the report indicates that the subject has metabolic dysregulation.

### Claim 22 (depends on 17)

The method of claim 17, wherein the at least one ratio comprises a plurality of ratios comprising Orn to Ile; Orn to Leu; and Orn to Val, and wherein if each of the plurality of ratios indicates an imbalance, the report indicates that the subject has or is at risk of developing the neurodevelopmental disorder.

### Claim 23 (depends on 17)

The method of claim 17, wherein:
the reference ratio is from a subset of autism spectrum disorder (ASD) subjects; and
the at least one ratio matches the reference ratio.

### Claim 24 (depends on 23)

The method of claim 23, wherein the at least one ratio is different from a ratio of concentrations of the at least two amine containing compounds in subjects that are developmentally delayed.

### Claim 25 (depends on 17)

The method of claim 17, wherein the reference ratio is from typically developing subjects; and
the at least one ratio does not match the reference ratio.

### Claim at position 21

26-30. (canceled)

### Claim 31 (depends on 17)

The method of claim 17, wherein the sample comprises a body fluid selected from the group consisting of blood, plasma, urine, sweat, tears, serum, stool, and saliva.

### Claim 32

(canceled)
